FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC

Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

Comment: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial